Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

GlaxoSmithKline Says First Quarter Profit Up 19%

By Pharmaceutical Processing | April 28, 2010

LONDON (AP) — GlaxoSmithKline, the world’s second-largest drug maker by revenue, on Wednesday reported a nearly 19 percent rise in first quarter profit, led by strong sales growth in Asia Pacific and emerging markets.

The pharmaceutical company said net profit for the first three months of the year was 1.34 billion pounds ($2.4 billion), up from 1.13 billion pounds in the first quarter last year.

Revenue rose 9 percent to 7.4 billion pounds.

The company said underlying sales — excluding the impact of pandemic products including Relenza and H1N1 vaccine — rose by 4 percent. Sales of H1N1 vaccine totaled 698 million pounds, or half the company’s vaccine sales.

Sales in the United States were down 1 percent, reflecting continuing pressure from generic drug competition. The company said sales were up 45 percent in Asia Pacific, 43 percent in emerging markets and 16 percent in Europe.

It increased its quarterly dividend to 15 pence from 14 pence.

GSK shares were up 1.7 percent at 1,234.5 pence on the London Stock Exchange following the news.

Chief Executive Andrew Witty said the company was on track to achieve 2.2 billion pounds of annual cost savings by 2012, with annual savings rising to 1.5 billion pounds by the end of this year.

The company said it had absorbed the impact of U.S. health care reform legislation in the first quarter, “and we expect to offset any further impact through continued operational performance.”

 

Related Articles Read More >

Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE